Gilead Sciences (GILD) Gross Margin (2009 - 2026)
Gilead Sciences (GILD) reported Gross Margin of 79.24% for Q1 2026, up 234.0% on a YoY basis from 23.72% in Q1 2025, and little changed quarter-over-quarter from 79.51% in Q4 2025.
Gilead Sciences (GILD) Gross Margin (2009 - 2026) Analysis & Trends
Gilead Sciences has reported Gross Margin for 18 years, with the latest figure at 79.24% in Q1 2026.
- For the quarter ending Q1 2026, Gross Margin rose 234.0% year-over-year to 79.24%; the trailing twelve-month figure through Mar 2026 stood at 79.35% (up 107.0% YoY), and the FY2025 full-year result was 78.83%, up 57.0% from the prior year.
- Gross Margin for Q1 2026 stood at 79.24%, roughly flat from 79.51% in the prior quarter.
- The five-year high for Gross Margin was 81.11% in Q4 2022, with the low at 70.62% in Q4 2023.
- Historically, Gross Margin has averaged 78.13% across 5 years, with a median of 78.39% in 2022.
- Annual changes were most pronounced in 2022 — Gross Margin jumped 1737 bps — and 2023, when it plunged 1049 bps.
- Gilead Sciences' Gross Margin stood at 81.11% in 2022, then retreated by 13 bps to 70.62% in 2023, then increased by 12 bps to 79.11% in 2024, then grew by 1 bps to 79.51% in 2025, then decreased by 0 bps to 79.24% in 2026.
- The last three Gross Margin figures came in at 79.24% (Q1 2026), 79.51% (Q4 2025), and 79.8% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 75.42% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 81.93% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 66.31% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 71.88% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 74.24% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 68.16% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 79.24% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -51.69% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 70.22% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 79.24% |
| Dec 31, 2025 | 79.51% |
| Sep 30, 2025 | 79.80% |
| Jun 30, 2025 | 78.81% |
| Mar 31, 2025 | 76.90% |
| Dec 31, 2024 | 79.11% |
| Sep 30, 2024 | 79.14% |
| Jun 30, 2024 | 77.80% |
| Mar 31, 2024 | 76.79% |
| Dec 31, 2023 | 70.62% |
| Sep 30, 2023 | 77.80% |
| Jun 30, 2023 | 78.15% |
| Mar 31, 2023 | 77.94% |
| Dec 31, 2022 | 81.11% |
| Sep 30, 2022 | 80.19% |
| Jun 30, 2022 | 76.96% |
| Mar 31, 2022 | 78.39% |
| Dec 31, 2021 | 63.74% |
| Sep 30, 2021 | 83.52% |
| Jun 30, 2021 | 77.64% |